Phaseline

Targets › CD105

CD105: drug programs, companies and trials

1 program from 1 company in 5 trials: 4 Phase 2, 1 Phase 1; Oncology; next expected readout Apr 2027.

Open in Phaseline: the race on CD105, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of WashingtonCD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
Plasmid DNA vaccine encoding multiple tumor-associated antigens (CD105/ENG, Yb-1/YBX1, SOX
ENG, YBX1, SOX2, CDH3, MDM2, CD105, YB1Phase 2Anatomic Stage IV Breast Cancer AJCC v8; Lung Non-Small Cell Carcinoma; Anatomic Stage IB Breast Cancer AJCC v8; HER2 Negative Breast CarcinomaApr 2027

Conditions

Anatomic Stage IV Breast Cancer AJCC v8 (2) Lung Non-Small Cell Carcinoma (1) Anatomic Stage IB Breast Cancer AJCC v8 (1) HER2 Negative Breast Carcinoma (1)

Modalities

mixed (1)

Companies

University of Washington (1)

Related targets

ENG (1) YBX1 (1) SOX2 (1) CDH3 (1) MDM2 (1) YB1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.